RxDoctor Payments DataLook up a doctor →

Mohd Qamar, MD

Interventional Cardiology · Skokie, ILNPI 1568759272

Payments from drug & device makers

$131,957in general payments, 2019–2025

Across 448 payments — averaging $294.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Imperative Care, Inc$50K
  • Novo Nordisk AS$32K
  • Novartis$23K
  • Chiesi USA, Inc.$13K
  • Siemens Medical Solutions USA, Inc.$5K
  • Penumbra, Inc.$4K
  • plus $5K from 30 others

What the payments were for

  • Speaking & faculty fees$16,56872%
  • Travel & lodging$1981%
  • Food & beverage$6,16627%
  • Education$1090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$131,957 in reported general payments places this provider in the 85th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$259,740
Medicare patients
857
Services billed
1,981

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban380$418,692
XareltoRivaroxaban222$256,717
JardianceEmpagliflozin65$69,329
OzempicSemaglutide38$39,954
BrilintaTicagrelor67$34,832
FarxigaDapagliflozin Propanediol40$34,463
EntrestoSacubitril/Valsartan27$27,480
Repatha SureclickEvolocumab40$21,794
Repatha SyringeEvolocumab13$13,008
Rosuvastatin Calcium564$7,872
MultaqDronedarone Hcl12$4,695
Ezetimibe138$4,192
Metoprolol Succinate340$4,002
Prasugrel Hcl70$3,473
Atorvastatin Calcium386$3,451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$410$418,692380 claims
Johnson & JohnsonXarelto$732$256,717222 claims
Boehringer IngelheimJardiance$403$69,32965 claims
AstraZenecaBrilinta, Farxiga$72$69,295107 claims
Novo NordiskOzempic$484$39,95438 claims
NovartisEntresto$22,560$27,48027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Skokie

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →